Search Results Heading

MBRLSearchResults

mbrl.module.common.modules.added.book.to.shelf
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
    Done
    Filters
    Reset
  • Discipline
      Discipline
      Clear All
      Discipline
  • Is Peer Reviewed
      Is Peer Reviewed
      Clear All
      Is Peer Reviewed
  • Reading Level
      Reading Level
      Clear All
      Reading Level
  • Content Type
      Content Type
      Clear All
      Content Type
  • Year
      Year
      Clear All
      From:
      -
      To:
  • More Filters
      More Filters
      Clear All
      More Filters
      Item Type
    • Is Full-Text Available
    • Subject
    • Country Of Publication
    • Publisher
    • Source
    • Target Audience
    • Donor
    • Language
    • Place of Publication
    • Contributors
    • Location
924 result(s) for "Brown, Jacqueline"
Sort by:
Caspian finds a friend
Caspian lives alone in a lighthouse surrounded by the cold gray-blue sea, longing for a friend; so one day he puts a message in a bottle and floats it away in the sea--but the friend who finds it is someone completely unexpected.
The experiences of seven women living with pelvic surgical mesh complications
IntroductionThis research sought to address a gap in the literature about women’s lived experience of pelvic surgical mesh complications, conducted by an insider researcher. An increasing number of women who have pelvic mesh surgeries with a view to improving their lives are experiencing life-altering complications. Without knowledge of these experiences we cannot know how best to care for affected women and prevent harm to further women.MethodsVan Manen’s hermeneutic phenomenological method was used. Seven women with pelvic mesh complications aged 43–69 years were enrolled using criterion sampling. Four of the seven women had surgical mesh for both pelvic organ prolapse (POP) and stress urinary incontinence (SUI), one for POP only, and two for SUI only. The women completed a modified ICIQ-LUTSqol questionnaire pre-interview and answered a separate global spiritual question adapted from the HOPE tool, a framework for spiritual assessment. Women were interviewed once using a semi-structured approach. Data were analysed using Van Manen’s selective reading technique and organized according to Lifeworld Existentials.ResultsModified ICIQ-LUTSqol scores ranged between 43 and 76 (range 19–76), with a mean of 62.2 (SD + 10.011) demonstrating significant impact on quality of life. Themes emerging from the analysis were: (1) lived space: 1(a) feeling powerless in the medical space, 1(b) living in a shrinking world; (2) lived body: 2(a) living with unrelenting pain, 2(b) inhabiting a body that can no longer be relied on; (3) lived time: 3(a) living in the gap between what was and what could have been; (4) lived other: 4(a) suffering in silence, 4(b) finding absolute Other and others as a source of strength.ConclusionsPelvic surgical mesh complications have an extensive adverse impact on the lifeworld of women experiencing complications. Failure to acknowledge mesh complications as treatment injury stalls the development of safer alternatives and changes needed to industry practices, regulation, clinical practice, and monitoring to keep women undergoing innovative urogynaecological procedures safe.
صبية سمراء تحلم
بمقاطع نثرية حيوية تحكي جاكلين ودسون عن النشوء خلال 1960 و1970 في الشمال والجنوب. ترعرعت في كارولينا الجنوبية ولاحقاً في بروكلين-نيويورك، وشعرت غالبا أنها في منتصف الطريق إلى بيتها في كل من هذين المكانين تصف في هذا الكتاب واقع وجودها مع مخلفات التمييز العرقي ووعيها المتزايد بحركة الحقوق المدنية ... لكن خلال مسيرتها كلها كان هناك دائما حب عائلي عميق وإعتزاز، ما جعل كل فرد من آل ودسون يقف منتصب القامة ويبرع بطريقته الخاصة، يتحدث نص ودسون الشفاف أيضا عن بهجة عثورها على صوتها عبر الكتابة، على الرغم من حقيقة أنها عانت كثيرا في المدرسة، وسيجد القارئ متعة في تتبع شغفها برواية القصص، وطريقتها في السرد، بينما تستعرض الشرارات الأولى للكاتبة التي ستصبح عليها في كل مقطع في هذا الكتاب هو في آن واحد سلس ومشحون بالعاطفة، وكل سطر يلقي الضوء على روح الطفلة وهي تبحث عن مكانها في هذا العالم.
Dropping Anchor, Setting Sail
The port city of Liverpool, England, is home to one of the oldest Black communities in Britain. Its members proudly date their history back at least as far as the nineteenth century, with the global wanderings and eventual settlement of colonial African seamen. Jacqueline Nassy Brown analyzes how this worldly origin story supports an avowedly local Black politic and identity--a theme that becomes a window onto British politics of race, place, and nation, and Liverpool’s own contentious origin story as a gloriously cosmopolitan port of world-historical import that was nonetheless central to British slave trading and imperialism. This ethnography also examines the rise and consequent dilemmas of Black identity. It captures the contradictions of diaspora in postcolonial Liverpool, where African and Afro-Caribbean heritages and transnational linkages with Black America both contribute to and compete with the local as a basis for authentic racial identity. Crisscrossing historical periods, rhetorical modes, and academic genres, the book focuses singularly on \"place,\" enabling its most radical move: its analysis of Black racial politics as enactments of English cultural premises. The insistent focus on English culture implies a further twist. Just as Blacks are racialized through appeals to their assumed Afro-Caribbean and African cultures, so too has Liverpool--an Irish, working-class city whose expansive port faces the world beyond Britain--long been beyond the pale of dominant notions of authentic Englishness. Dropping Anchor, Setting Sail studies \"race\" through clashing constructions of \"Liverpool.\"
Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics
To investigate breast cancer-specific mortality by early breast cancer (EBC; Stages I-IIIC) subtype; incidence of high-risk indicators for recurrence (defined in monarchE trial); and mortality risk difference by those who did/did not meet these criteria. Analyses included patients with initial EBC diagnosis between 2010-2015 from Surveillance, Epidemiology, and End Results (SEER) data (n = 342,149). Cox proportional hazards models and Kaplan-Meier estimates examined mortality among 228,031 patients, by subtype (hormone receptor [HR]-positive [+], human epidermal growth factor receptor-2 [HER2] negative [-]; triple negative [TNBC]; HR+, HER2+; HR-, HER2+). Incidence and mortality among patients who did/did not meet monarchE clinicopathological high-risk criteria were examined. Among patients with HR+, HER2- EBC, histologic Grade 3 (vs. Grade 1) was the most influential factor on mortality (hazard ratio, 3.61; 95%CI, 3.27, 3.98). Among patients with TNBC, ≥4 ipsilateral axillary positive nodes (vs. node negative) was the most influential factor on mortality (hazard ratio, 3.46; 95%CI, 2.87, 4.17). For patients with HR-, HER2+ or HR+, HER2+ EBC, tumor size ≥5 cm (vs. <1 cm) and ≥4 ipsilateral axillary positive nodes were the most influential factors on mortality. The 60-month mortality rate for the 12% of patients within the HR+, HER2- EBC group meeting monarchE clinicopathological high-risk criteria was 16.5%, versus 7.0% (Stage II-III and node positive) and 2.8% (Stage I or node negative) for those not meeting criteria. The 60-month mortality rate for patients with TNBC was 18.5%. Mortality risk and the relative importance of risk factors varied by subtype. monarchE clinicopathological high-risk criteria were associated with increased mortality risk among patients with HR+, HER2- EBC. Patients with HR+, HER2- EBC, and monarchE clinicopathological high-risk criteria experienced risk of mortality similar to patients with early TNBC. These data highlight a high unmet need in this select patient population who may benefit most from therapy escalation.
Unspoken Indigenous History on the Stage: The Postcolonial Plays of Jack Davis
Literary scholars and linguists have argued extensively that language is not simply a purely representational vehicle of thought but its determining medium, whose ordering powers not only shape cognizance of reality but are also actively involved in processes of imperialism and cultural erasure. It is the determinative yet slippery quality of language, prompting the loss of meaning in attempts at translation, that colonial powers manipulated to violent effect and which, as enacted in the plays of Nyoongah Indigenous Australian playwright Jack Davis, continue to haunt history and the present. This article considers how a history and culture made unspeakable by colonialism through the erasure of Indigenous Australian oral traditions, languages, and historical perspectives is translated on to the Anglophone stage in the plays of Davis, one of the first Indigenous playwrights to be published and performed internationally, and how this was received by the witnessing audience. Davis achieves this theatrical translation not only through the negotiation and manipulation of colonial language and verbatim history alongside Indigenous languages, enacting a kind of linguistic double consciousness, but also through physical theatre and dance. The latter are the central means of communicating meaning and knowledge in Nyoongah culture. Jacqueline M. Brown is a graduate student at Worcester College, University of Oxford, studying for a Master of Studies in English (1900–present). This article received first prize in the 2022 TORCH Reimagining Performance Network Graduate Essay Prize competition run in collaboration between the University of Oxford and New Theatre Quarterly. For more information on the Reimagining Performance Network, see .
Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma
Abstract Background Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. We aimed to evaluate the feasibility of next-generation sequencing (NGS) testing of circulating cell-free tumor DNA (ctDNA) in patients with ACC, to characterize the genomic landscape of alterations, and to identify potential clinically actionable mutations. Methods Retrospective analysis of genomic data from 120 patients with ACC who had ctDNA testing between 12/2016 and 10/2021 using Guardant360 (Guardant Health, CA) was performed. ctDNA NGS analysis interrogated single nucleotide variants, fusions, indels, and copy number amplifications of up to 83 genes. The frequency of genomic alterations, landscape of co-occurring mutations, and pathogenic/likely pathogenic alterations with potential targeted therapies was identified. The prevalence of alterations identified in ctDNA was compared to those detected in tissue using a publicly available database (cBioPortal). Results The median age of this cohort was 53 years (range 21-81), and 56% of patients were female. Ninety-six patients (80%) had ≥1 somatic alteration detected. TP53 (52%), EGFR (23%), CTNNB1 (18%), MET (18%), and ATM (14%) were found to be the most frequently altered genes in ACC samples. Pathogenic and/or likely pathogenic mutations in therapeutically relevant genes were observed in 56 patients (47%) and included EGFR, BRAF, MET, CDKN2A, CDK4/6, and ATM. The most frequent co-occurring mutations were EGFR + MET (9%), MET + CDK4 (7%), EGFR + CDK4 (7%), and BRAF + MET (7%). The frequencies of mutations detected in ctDNA were similar to those detected in tissue. Conclusions Utilizing blood-based NGS to characterize genomic alterations in advanced ACC is feasible in over 80% of patients. Almost half of the patients had actionable mutations with approved therapies in other cancers. This approach might inform the development of personalized treatment options or identify clinical trials available for this aggressive malignancy. Developing a comprehensive understanding of the genomic landscape of adrenocortical carcinoma using ctDNA is an unmet need that may pave the way to incorporating target-based therapies. This article presents the largest study to date evaluating the feasibility of a blood-based ctDNA approach in revealing clinically significant alterations and co-existing genomic alterations in adrenocortical carcinoma.
Landscape of copy number aberrations in esophageal squamous cell carcinoma from a high endemic region of South Africa
Background Esophageal squamous cell carcinoma (ESCC) is an aggressive cancer with one of the highest world incidences in the Eastern Cape region of South Africa. Several genome wide studies have been performed on ESCC cohorts from Asian countries, North America, Malawi and other parts of the world but none have been conducted on ESCC tumors from South Africa to date, where the molecular pathology and etiology of this disease remains unclear. We report here tumor associated copy number changes observed in 51 ESCC patients’ samples from the Eastern Cape province of South Africa. Methods We extracted tumor DNA from 51 archived ESCC specimens and interrogated tumor associated DNA copy number changes using Affymetrix® 500 K SNP array technology. The Genomic Identification of Significant Targets in Cancer (GISTIC 2.0) algorithm was applied to identify significant focal regions of gains and losses. Gains of the top recurrent cancer genes were validated by fluorescence in situ hybridization and their protein expression assessed by immunohistochemistry. Results Twenty-three significant focal gains were identified across samples. Gains involving the CCND1, MYC, EGFR and JAG1 loci recapitulated those described in studies on Asian and Malawian cohorts. The two most significant gains involved the chromosomal sub-bands 3q28, encompassing the TPRG1 gene and 11q13.3 including the CTTN , PPFIA1 and SHANK2 genes . There was no significant homozygous loss and the most recurrent hemizygous deletion involved the B3GAT1 gene on chromosome 11q25. Focal gains on 11q13.3 in 37% of cases (19/51), consistently involved CTTN and SHANK2 genes. Twelve of these cases (23,5%), had a broader region of gain that also included the CCND1 , FGF19, FGF4 and FGF3 genes. SHANK2 and CTTN are co-amplified in several cancers, these proteins interact functionally together and are involved in cell motility. Immunohistochemistry confirmed both Shank2 (79%) and cortactin (69%) protein overexpression in samples with gains of these genes. In contrast, cyclin D1 (65%) was moderately expressed in samples with CCND1 DNA gain. Conclusions This study reports copy number changes in a South African ESCC cohort and highlights similarities and differences with cohorts from Asia and Malawi. Our results strongly suggest a role for CTTN and SHANK2 in the pathogenesis of ESCC in South Africa.
Clinical outcomes of lutetium-177–PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer
Abstract Background Lutetium-177 (177Lu)–PSMA-617 is a beta-emitting radioligand approved for treatment of metastatic castration-resistant prostate cancer (mCRPC), despite the underrepresentation of Black patients in pivotal trials. We analyzed outcomes of 177Lu-PSMA-617 in a racially diverse cohort. Methods Retrospective analysis of patients with mCRPC treated with 177Lu-PSMA-617 was conducted at the Emory Winship Cancer Institute. Primary outcomes assessed were progression-free survival (PFS), overall survival (OS), and prostate-specific antigen (PSA) reduction ≥50% (PSA50). Cox proportional hazard models were used for univariate and multivariate OS and PFS, and logistic regression was used for PSA50 analysis. Results Among 163 patients treated with 177Lu–PSMA-617, 97 (59.5%) self-identified as White or other racial groups and 66 (40.5%) self-identified as Black. On univariate analysis, Black patients had comparable OS, PFS, and PSA50 responses to non-Black patients, with a trend toward improved outcomes (OS HR: 0.82, P = .446; PFS HR 0.92, P = .655; PSA50 OR = 1.79, P = .088). Multivariate analysis demonstrated a non-significant prolonged PFS and reduction in mortality risk for Black patients (PFS HR: 0.65, P = .106; OS: HR 0.59, HR P-value .081). The odds of a PSA50 response were 2.45 times higher for Black patients (OR = 2.45, P = .027). Conclusions In our racially diverse cohort of patients with mCRPC, Black patients had PFS and OS comparable to non-Black patients, although wide confidence intervals limit definitive conclusions. Black patients had a significantly greater odds of achieving a PSA50 response. Our findings suggest efficacy of 177Lu-PSMA-617 among Black patients in real-world settings and underscore the importance of improved representation in prospective studies.